Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monash IVF GroupMNIVF 84 12-1 Month Momentum % is N/A% as of Aug. 10, 2026. GuruFocus rates MNIVF with a GF Score™ of 84/100 and a GF Value™ of $0.81. The stock has 7 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Monash IVF Group ranks worse than 54.46% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-10), Monash IVF Group's 12-1 Month Momentum % is N/A%.
The industry rank for Monash IVF Group's 12-1 Month Momentum % or its related term are showing as below:
MNIVF's 12-1 Month Momentum % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -7.06 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Monash IVF Group (OTCPK:MNIVF) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Monash IVF Group 12-1 Month Momentum % Related Terms
MNIVF vs TMO, DHR, IDXX: 12-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Monash IVF Group's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group 12-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's 12-1 Month Momentum % falls into.
Monash IVF Group (OTCPK:MNIVF) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group (MNIVF) has a 12-1 Month Momentum % of N/A% as of Aug. 10, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Monash IVF Group and its competitors. According to the industry distribution chart, Monash IVF Group ranks #116 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 54.5%.
Is Monash IVF Group's 12-1 Month Momentum % too high?
Monash IVF Group's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Monash IVF Group ranks #116 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Monash IVF Group has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's 12-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #116 out of 213 companies for 12-1 Month Momentum %. This places Monash IVF Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Monash IVF Group and its competitors. Monash IVF Group's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current 12-1 Month Momentum % of N/A%. The stock's GF Value™ is $0.81, compared to a current price of $0.40 — trading 50.6% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Monash IVF Group's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current 12-1 Month Momentum % is N/A% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 50.6% below its estimated GF Value™ of $0.81.
Key valuation signals for MNIVF:
12-1 Month Momentum %: N/A%
GF Value™: $0.81 vs. price of $0.40 (50.6% below fair value)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
84GF Score
Get the complete analysis for MNIVF
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
